Diabetes mellitus following liver transplantation in patients with hepatitis C virus: Risks and consequences

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 531-538

  Gane, E J ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Diabetes mellitus; hepatitis C; immunosuppression; liver transplantation

Indexed keywords

ALISPORIVIR; ANTIVIRUS AGENT; CYCLOSPORIN A; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SCY 635; TACROLIMUS; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; GRAFT INFECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; METABOLIC SYNDROME X; NONHUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; SURVIVAL; TREATMENT RESPONSE;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; RISK FACTORS;

EID: 84857640535     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03854.x     Document Type: Review

References (52)

1. Gane EJ,. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36-S44.
2. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
3. Chen T, Jia H, Li J, Chen X, Zhou H, Tian H,. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: Meta-analysis of clinical studies. Transpl Int 2009; 22: 408-415.
4. Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG,. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation 2006; 82: 1625-1628. (Pubitemid 46035640)
5. Baid S, Cosimi AB, Farrell ML, et al,. Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066-1072. (Pubitemid 32924079)
6. Allison MED, Wreghitt T, Palmer CR, Alexander GJM,. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139.
7. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL,. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
8. White DL, Ratziu V, El-Serag HB,. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J Hepatol 2008; 49: 831-844.
9. Hui JM, Sud A, Farrell GC, et al,. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-1704. (Pubitemid 37500434)
10. Vanni E, Abate ML, Gentilcore E, et al,. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009; 50: 697-706.
11. Sabharwal S, Delgado-Borrego A, Chung RT,. Extrahepatic hepatitis C virus after transplantation: Diabetes and renal dysfunction. Liver Transpl 2008; 14 (Suppl 2): S51-S57.
12. Cua IHY, Hui JM, Kench JG, George J,. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 723-731.
13. Kawaguchi T, Yoshida T, Harada M, et al,. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508. (Pubitemid 39435150)
14. Milner KL, van der Poorten D, Trenell M, et al,. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138: 932-941.e3.
15. Bigam DL, Pennington JJ, Carpentier A, et al,. Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. Hepatology 2000; 32: 87-90. (Pubitemid 30432370)
16. Delgado-Borrego A, Liu Y-S, Jordan SH, et al,. Prospective study of liver transplant recipients with HCV infection: Evidence for a causal relationship between HCV and insulin resistance. Liver Transpl 2008; 14: 193-201. (Pubitemid 351267276)
17. Fabrizi F, Messa P, Martin P, Takkouche B,. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: A meta-analysis. Int J Artif Organs 2008; 31: 675-682.
18. Veldt BJ, Poterucha JJ, Watt KDS, et al,. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413.
19. Foxton MR, Quaglia A, Muiesan P, et al,. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922-1929. (Pubitemid 44024965)
20. Hanouneh IA, Feldstein AE, McCullough AJ, et al,. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293.
21. El-Serag HB, Tran T, Everhart JE,. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468. (Pubitemid 38182303)
22. Veldt BJ, Chen W, Heathcote EJ, et al,. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862. (Pubitemid 351945553)
23. El-Serag HB, Johnson ML, Hachem C, Morgana RO,. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009; 136: 1601-1608.
24. Berenguer M, Palau A, Aguilera V, Rayõn JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687. (Pubitemid 351287553)
25. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
26. Moucari R, Forestier N, Larrey D, et al,. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010; 59: 1694-1698.
27. Romero-Gõmez M, Fernández-Rodríguez CM, Andrade RJ, et al,. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-727.
28. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN,. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009; 54: 2699-2705.
29. Fung JJ, Eliasziw M, Todo S, et al,. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183: 117-125. (Pubitemid 26260143)
30. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A, The UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial. Lancet 2002; 360: 1119-1125.
31. 0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-1638. (Pubitemid 38780525)
32. Irish WD, Arcona S, Bowers D, Trotter JF,. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: Outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11: 1676-1685.
33. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K,. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288. (Pubitemid 37314838)
34. Chatterji U, Lim P, Bobardt MD, et al,. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol 2010; 53: 50-56.
35. Berenguer M, Royuela A, Zamora J,. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis. Liver Transpl 2007; 13: 21-29. (Pubitemid 46099970)
36. Berenguer M, Aguilera V, San Juan F, et al,. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204-1209.
37. Firpi RJ, Soldevila-Pico C, Morelli GG, et al,. The use of cyclosporine for recurrent hepatitis C after liver transplant: A randomized pilot study. Dig Dis Sci 2010; 55: 196-203.
38. ReViS-TC Study Group. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: A large, multicenter cohort study. Transplantation 2011; 92: 334-340.
39. Oton E, Barcena R, Moreno-Planas JM, et al,. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose Peg-interferon and ribavirin. Am J Transplant 2006; 6: 2348-2355. (Pubitemid 44359420)
40. Picciotto FP, Tritto G, Lanza AG, et al,. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465. (Pubitemid 46185706)
41. Carriõn JA, Navasa M, García-Retortillo M, et al,. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007; 132: 1746-1756. (Pubitemid 46695723)
42. Selzner N, Renner EL, Selzner M, et al,. Antiviral treatment of recurrent hepatitis C after liver transplantation: Predictors of response and long-term outcome. Transplantation 2009; 88: 1214-1221.
43. Cescon M, Grazi GL, Cucchetti A, et al,. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782-789.
44. Berenguer M, Aguilera V, Prieto M, et al,. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12: 762-767.
45. Laskow DA, Neylan JF, III, Shapiro RS, Pirsch JD, Vergne-Marini PJ, Tomlanovich SJ,. The role of tacrolimus in adult kidney transplantation: A review. Clin Transplant 1998; 12: 489-503. (Pubitemid 28542799)
46. Dumortier J, Bernard S, Bouffard Y, Boillot O,. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006; 12: 659-664.
47. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-428.
48. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1115.
49. Levy G, Grazi GL, Sanjuan F, et al,. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006; 12: 1464-1472. (Pubitemid 44594275)
50. Shenoy S, Hardinger KL, Crippin J, et al,. A randomized, prospective, pharmacoeconomic trial of Neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients. Liver Transpl 2008; 14: 173-180. (Pubitemid 351267273)
51. Saliba F, Lakehal M, Pageaux GP, et al,. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: An observational multicenter study. Liver Transpl 2007; 13: 136-144. (Pubitemid 46099983)
52. Rendina M, Rossi G, D'Amico D, et al,. Conversion to cyclosporine therapy induces significant benefits in liver transplant recipients on tacrolimus with new onset diabetes: The DIALIVER study [abstract]. Am J Transplant 2009; 9 (Suppl 2, Abstract #471): 328.